SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Advanced Medical Isotope Corp. (ADMD)

ADMD RSS Feed
Add ADMD Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Eltp, Boot Hill, JayBPee, Popeye, Tcsxyz
Search This Board: 
Last Post: 10/23/2017 10:45:29 AM - Followers: 420 - Board type: Free - Posts Today: 1

 

Advanced Medical Isotope Corporation
 

The strategic market sector of Advanced Medical Isotope Corporation (AMI) is isotope applications.  Currently, the Company is engaged in the development of RadioGel™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The IsoPet Solutions division of AMI is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. AMI is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.

The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.

What is RadioGel™?

RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor.  This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days.  This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.

What are the advantages of RadioGel™?

Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMI believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.

Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.

•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMI’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.

•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMI’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.

•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMI’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.

•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.

What is the market for RadioGel™?

Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.

What are the steps for FDA clearance?

AMI met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and AMI team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.

August 2016, AMI announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, AMI anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see latest company press releases for continual updates on this evolving process).

Are there other markets for RadioGel™? 

March 15th, 2016, AMI announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.

The IsoPet Solutions division will focus on bringing AMI’s yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers. There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat.  IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. AMI expects the initial treatments to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos and anticipate offering RedioGel™ for vet treatments.

What is Brachytherapy?

Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.  According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.  It is estimated that the U.S. market represents approximately half of the global market.  AMI believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers.  The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.

Press Releases since 2017 Change in Management & Directors

Dec 20, 2016,  AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017,  AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017,  AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017,  AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017,  AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017,  Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017,  AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017,  ADMD Makes Significant Improvement to its RadioGel(TM) Brachytherapy Product
Jul 27, 2017,  ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017,  Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017,  Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™


Independent Analyst Research and Price Target

Sep 7, 2017, Van Leeuwenhoek Research Increases Valuation of ADMD to USD $35-$55 million USD or $0.66 - $1.00 per share

Presentation from President & CEO, Dr. Mike Korenko! 

Aug 1, 2017,  LINK HERE


STOCK SYMBOL: OTCQB: ADMD

COMPANY WEBSITE
FACEBOOK
TWITTER

UPDATED 8/24/2017

Outstanding Shares 51,200,000
Preffered Series A     4,000,000

 
SureTrader
Interactive Brokers Advertisement
ADMD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#65430  Sticky Note Radiogel, Radiogel for Vet will be a major obesestupidmouse 08/05/17 07:15:12 PM
#65067  Sticky Note News out, significant improvement on the manufacturing process Eltp 07/11/17 08:49:02 AM
#63480  Sticky Note interesting eh ????? if no profit then what mick 03/05/17 12:12:44 PM
#62930  Sticky Note I know this was talked about but I Popeye 01/23/17 07:55:30 PM
#60262  Sticky Note This stock is bigger than the company. If Tcsxyz 07/27/16 08:25:42 PM
#47440  Sticky Note The only topic to be discussed here is ADMD IH Dan (Retired) 09/27/15 02:45:52 PM
#66555   I believe it will. If a partnership gets Popeye 10/23/17 10:45:29 AM
#66553   Chief Slapaho 10/22/17 10:11:07 PM
#66552   Third run will be massive Eltp 10/22/17 04:08:45 PM
#66550   All talk and no action just like ADMD. tilltom 10/22/17 02:33:22 PM
#66549   I’ll keep loading. Watch and learn, again! GLTY $ADMD Popeye 10/22/17 02:24:48 PM
#66548   ROTFLMAO! Another buying opportunity is just what this tilltom 10/22/17 09:37:47 AM
#66547   There is no FDA approval or revenue yet Eltp 10/21/17 06:25:51 PM
#66546   I know! Isn’t it great!! Loading zone!! $ADMD Popeye 10/21/17 06:03:09 PM
#66545   I'll be the last one laughing....you can count WALLnut 10/21/17 03:53:20 PM
#66544   Device that cures cancer with "respected" people in Tcsxyz 10/21/17 10:08:21 AM
#66543   There is zero interest in this POS. Its tilltom 10/20/17 09:29:23 AM
#66542   Or a paint to the downside to scare Popeye 10/19/17 05:15:24 PM
#66541   Correct. No one is buying because they know Chief Slapaho 10/19/17 04:51:59 PM
#66540   It's called a 'prop up' buy at the Chief Slapaho 10/19/17 04:51:02 PM
#66538   How do you think it turned green for WALLnut 10/19/17 04:12:42 PM
#66537   The better question is why is nobody buying tilltom 10/19/17 04:04:02 PM
#66535   I have no clue who is dumping this Chief Slapaho 10/19/17 03:39:38 PM
#66534   True in so many ways. LMAO. WALLnut 10/19/17 03:37:57 PM
#66533   I bet Jim Katzaroff feeling pretty good right CatfishHunter 10/19/17 03:33:26 PM
#66532   Yescarta passed today. Everyday they drag this out Tcsxyz 10/19/17 03:27:04 PM
#66529   Wow, a whopping 1 share traded today! LMFAO. Chief Slapaho 10/19/17 02:01:25 PM
#66526   Hey Muffinlover. I caught this comment from your Popeye 10/19/17 09:36:00 AM
#66524   Apparently Maren the same daughter or wife who CatfishHunter 10/18/17 07:49:28 PM
#66522   Not really. A lot of guys date younger; Chief Slapaho 10/18/17 07:28:26 PM
#66521   I know it’s not his daughter, she is Eltp 10/18/17 07:19:43 PM
#66520   It is not his daughter. It's his wife. Chief Slapaho 10/18/17 06:53:59 PM
#66519   He is obviously Katzaroff defending his daughter that Eltp 10/18/17 06:44:05 PM
#66518   I did indeed. Just a reminder of what Chief Slapaho 10/18/17 06:30:32 PM
#66517   Jim's an egotistical misogynistic idiot who has no CatfishHunter 10/18/17 06:01:57 PM
#66516   Don't need to beat a dead horse? You microcaptrdr24 10/18/17 05:42:45 PM
#66515   He is not Katzaroff. And I don't care Chief Slapaho 10/18/17 05:38:01 PM
#66514   You must have replied to the wrong post. Tcsxyz 10/18/17 05:37:46 PM
#66513   Lmao I know. They can't tell that's him microcaptrdr24 10/18/17 05:32:39 PM
#66511   He's Katzaroff FYI microcaptrdr24 10/18/17 05:29:31 PM
#66510   Hysterical how you all called Katzaroff king of CatfishHunter 10/18/17 05:27:28 PM
#66508   Another one that sees it correctly. Tcsxyz 10/18/17 05:23:32 PM
#66507   Wow. Couldn't be more off. 100 shares traded Chief Slapaho 10/18/17 05:21:55 PM
#66506   Thank you for this post, Muffinlover. With all Chief Slapaho 10/18/17 05:21:01 PM
#66504   Hi Mr Katzaroff. Nice to pop in CatfishHunter 10/18/17 05:03:05 PM
#66502   Say what you will but I’m certainly happy Popeye 10/18/17 02:50:05 PM
#66501   It's a scam only if you lose money. CatfishHunter 10/18/17 02:48:07 PM
#66499   Smart money played the prior runs holding now CatfishHunter 10/18/17 02:23:07 PM
#66498   I wish I had a dollar for every tilltom 10/18/17 02:14:46 PM
#66497   This will run again and the wait won’t Popeye 10/18/17 02:00:27 PM
#66496   Spot on! Chief Slapaho 10/18/17 01:01:11 PM
#66495   That is why there is zero volume buying Chief Slapaho 10/18/17 12:14:13 PM
#66494   Dr Korenko's accomplishments in less then a year. WALLnut 10/18/17 09:31:45 AM
#66491   Nobody is buying this POS. Its years away tilltom 10/17/17 02:55:42 PM
#66488   Most importantly, selling continues to dry up. Looking Popeye 10/17/17 12:59:57 PM
#66487   And there are only 1500 shares traded today. Chief Slapaho 10/17/17 12:43:05 PM
PostSubject